Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada
MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched MYFEMBREE® (relugolix/estradiol/norethindrone acetate) in Canada. In Ju
(Financial Post, 2025-10-07T11:30:25Z)